Continuing its progress in addressing different cancer types across different geographies, immuno-oncology blockbuster Tecentriq (atezolizumab) has secured Chinese approval in extensive-stage small cell lung cancer (ES-SCLC).
Last year, Roche (ROG: SIX) became the first company to offer an immuno-oncology option for people with this kind of cancer, when it won approval in Europe and in the USA, ahead of rival options from AstraZeneca (LSE: AZN) and Merck & Co (NYSE: MRK).
Approval in China will help the Swiss cancer giant entrench its lead, with Tecentriq taking in 1.88 billion Swiss francs ($1.9 billion) in 2019, up 143% from the year before. In the fourth quarter revenues were 248 million Swiss francs, up 136% from the like period of 2018.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze